Antiviral prodrugs of etv and formulations thereof

A compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein
• R1 is H or is X-Lm,
• m=1 or 2;
• X-Lm is —C(═O)L, —C(═O)OL, —C(═O)NH(L), —C(═O)N(L)2, —CH(R)OC(═O)L, —C(═O)CH(R)—NH(L), —C(═O)CH(R)—N(L)2, —P(═O)(NHL)2, —P(═O)(NHL)(NL2), or —P(═O)(NL2)2,
• each L is independently selected from (C1-22, linear and branched)alkyl, (C3-22, linear and branched)alkenyl, (C3-7)cycloalkyl, (CHR)n-phenyl wherein n=0 or 1, and —CHR—N(R)2;
• or R1 is —OCH(R)OP(═O)(OH)2, a phosphate residue or its derivative residue comprising a monophosphate, a diphosphate, a triphosphate, a phosphonate, a phosphate polyester, a phosphate monoamidate, a phosphate diamidate, a phosphorothioate, a phosphoroselenoate, or a phosphoroboranoate;
• R is H, (C1-22)alkyl, (C3-22)alkenyl, (C3-7)cycloalkyl, or (C6-C12)aryl;
• R2 is H or is X-Lm;
• or R2 is —OCH(R)OP(═O)(OH)2, a phosphate residue or its derivative residue comprising a monophosphate, a diphosphate, a triphosphate, a phosphonate, a phosphate polyester, a phosphate monoamidate, a phosphate diamidate, a phosphorothioate, a phosphoroselenoate, or a phosphoroboranoate,
• and wherein R1 and R2 are not simultaneously H.